Introduction
The Fourth Biennial Prostate Cancer Charitable Trust Meeting was as exciting and interesting as its predecessors. In summarizing, or rather perhaps commenting on the meeting, it is worth ®rst of all recalling the fundamental ideas that underlie the development of a cancer, ideas going back to the early years of this century, namely that cancer is a somatic evolutionary process. Each cancer is an independent evolutionary event in which mutations are selected because they give an advantage to the outgrowth of the tumour, not necessarily, at least initially, increasing its rate of growth. The process is stepwise and, since there is no sexual exchange, each mutation must occur within the clone that is an expansion of the previous mutation. Mutations are considered here in the broad sense to include stable changes in genetic expression, namely epigenetic events. These are now realized primarily to be changes in methylation which affect gene expression, and which from the cancer's point of view, are effectively as stable as true mutations, namely changes in DNA sequence. Each change in gene expression or mutation is likely to introduce a multitude of other changes. One of the challenges, therefore, when analysing the phenotype of cancer cells at different stages of their evolution, is to identify the primary changes, namely those that do involve a gene mutation or clearly identi®-able epigenetic change. The fundamental understanding of a cancer is the identi®cation of those genetic steps and the understanding of their function, which in turn de®nes the nature of their selective advantage to the tumour. From this knowledge comes the hope of new approaches to prevention, early detection, and treatment. Judah Folkman did, however, remind us that very effective treatments such as the initial treatment of diabetes using insulin, have been implemented before their basis has been properly understood.
Amongst the new techniques at the direct genetic level are the comprehensive karyotype analyses that can now be carried out using multicolour¯uorescence in situ hybridization (FISH). In addition, we now have to hand the extraordinarily comprehensive information on the complete set of human genes and their sequences that is coming out of the Human Genome Project.
Sources of materials and prostate cancer models
The castrated rat model, described by Jack Schealken, is impressive because it may distinguish the involvement of the initial stem cell from the next level of proliferating cell, which expands the cell population before it reaches its ®nally differentiated state. The analogy with the colon is clear. Here the stem cell (S) is at the bottom of the crypt, above which there is an intermediate proliferating zone of cells and then ®nally above this the terminally differentiated cells which are eventually shed into the lumen as they undergo apoptosis. Theoretical models 1 strongly suggest that it is the intermediate proliferating set of cells which may be the key cells from which a cancer is initiated rather than the stem cells. A genetic change in the stem cell leads to immediate exponential proliferation in a way that is incompatible with our knowledge of the way that tumours develop, and such cells are probably readily eliminated by apoptosis. Genetic changes at the level of the intermediate proliferating zone can lead to a metastable state, namely a stable turnover, which in the colon produces a polyp or adenoma, and this seems to be analogous with the small lesions shown by Judah Folkman. These are, I believe, not dormant cells but cells which have expanded in number to a level where there is a continuing turnover of a population within which further mutations can occur, giving a further selective advantage to the tumour.
New sources of human prostate cancer cells are desperately needed to further studies of genetic changes and their associated functions. Amongst these, Robert Vessella's series of xenografts may provide an important new source of cells. It still seems to be very dif®cult, more so than with other cancers, to grow established cell lines from human prostate cancers. However, John Rhim 2 described an approach to transformation which appears to be very successful. It seems to me more important to apply this to tumour cells than normal prostate epithelium because, although transformation may change the karyotype and some aspects of gene expression, it is most unlikely to in¯uence the actual mutations that have occurred in the cancer. Thus, an immortalized cell population would, at the very least, be a valuable source of material in which to search for new mutations in appropriately chosen candidate genes. It will then always be possible to assess such mutations in primary tumour material, including the early PIN lesions, which might then give some clues as to which are the most important early steps in the development of a prostate cancer. The culture system using bone marrow feeders described by Noel Clark remains of great interest and needs further development as a source of material.
Finally, there is Norman Greenberg's spectacularly successful mouse model 3 in which SV40 genes are targeted to the appropriate prostate tissue, giving a very high yield of spontaneous tumours. This provides, in principle, a much more relevant model based on spontaneous tumorigenesis than the more usual xenograft model. However, it still needs further investigation to explore whether the pathways followed in this model are those which are relevant to the human situation. This again can be directly tested for by looking for the mutations equivalent to those in the mouse model, in appropriate human primary material. The pathology and the androgen dependence do strongly suggest that Norman Greenberg's model really may be an appropriate mouse equivalent to human prostate cancer. This, together with the other developments described at this meeting, indicates a considerable advance in the availability of sources of material over what had been described just two years ago.
Genetic changes in prostate cancer
It is still surprising that so few speci®c mutations have been described in prostate cancer. Perhaps the success that has been achieved in this respect with colon cancer does not readily extend to cancers of other tissues. Yet even mutations in, for example, ras and p53 or the genes for growth factors and their receptors have not been identi®ed. Many clues to the existence of tumour suppressor mutations have come from family studies based on Knudson's hypothesis, which relates germline to somatic changes. This is how the APC gene, whose mutations are responsible for familial adenomatous polyposis, was found and through that the various mutations in the wnt pathway, including E-cadherin and b-catenin. It is now clear that mutations in APC are the earliest changes in more than 80% of colorectal cancers, and it seems probable that this pathway will be important in the earliest stages of most carcinomas.
Ros Eeles 4 showed that there is still a considerable problem in identifying germline genes for familial prostate cancer, in spite of the existence of very large bodies of data. This is probably because of heterogeneity, in the sense that there may be a variety of different sorts of mutations that can give rise to small clusters of families, making it dif®cult to identify any particular mutation. It may be pure chance that in colon cancers there have been genes such as APC, and the mismatch repair genes, especially hMLH1 and hMSH2, and in breast cancer BRCA1 and BRCA2, which give rise to a relatively high proportion of the familial versions of these cancers. Certainly in colon cancer, it has become clear that there is a variety of genes that can give rise to much rarer, and often clinically distinct, forms of familial colon cancer such as the Puetz ± Jegher and juvenile polyposis families. Perhaps that is the general situation for prostate cancer, creating a considerable problem for the application of classical genetic approaches to ®nding linkage with marker genes and so enabling positional cloning.
Nevertheless, the linkage with Xq27 ± 28 described by Ros Eeles is very intriguing. It seems too much of a coincidence that this is exactly the region that has been identi®ed for familial testis cancer. There is, therefore, a clear possibility that when the gene for testis cancer is identi®ed through positional cloning it will also turn out to be a gene whose mutations give rise to susceptibility to prostate cancer.
There is another category of genetic susceptibility, as previously discussed at these meetings, identi®ed through APC missense mutations that have a relatively low penetrance but nevertheless give rise to a much increased risk of getting either colorectal cancers or, more speci®cally, adenomas. 5, 6 These are mutations which have a much less severe effect than the classical nonsense or truncating mutations in APC which lead to FAP. They are likely to have a higher frequency in the population, anywhere from 1 in 1000 to even a few percent, because of the very mild, if any, selective disadvantage associated with them given their incomplete penetrance. The challenge is to identify candidate genes in which missense variations give rise to an increased susceptibility, though often not giving rise to an obvious familial concentration. One obvious way to ®nd such variation is to search for it in true sporadic cases of prostate cancer with a relatively early age of onset. It is important to rule out, as far as possible, in such studies a familial history of the cases under investigation.
There are two clearly different explanations for such sporadic cases. One is that they are new mutations with severe effects, such as the truncating mutations in the APC gene. The other is that they are due to relatively low frequency, low penetrance genes which nevertheless have a much higher frequency in the population than mutations kept at a very low frequency by the classical balance between mutation and selection. Because of their low penetrance, even if it is 30 ± 50%, the missense variants as described above will often not give rise to familial clustering because the probability of having two or more cases affected in a family is small. Screening in families is only likely to be relevant with highly penetrant mutations giving rise to essentially Mendelian inheritance. Eventually, when a gene mutation can be tested for in the family, then this provides the basis for screening. Otherwise, there must be a high a priori probability that an individual with any sign of disease in such a family actually does have prostate cancer. This is very different from screening in the general population, where most individuals have a relatively low risk of getting prostate cancer. In families, therefore, it may be legitimate to accept a lower level, say, of PSA as an indicator of the presence of disease, because the probability of false positives in the family, given the a priori high probability of having a cancer, is much lower than in the population at large. There is evidence for this, for example, in using ultrasound to screen for ovarian cancer in families at risk because of BRCA1 or BRCA2 mutations.
It may also be of interest to test for potential susceptibility effects associated with polymorphic variation, for example, in the genes involved in androgen biosynthesis. The dif®culty here is that large studies may well give rise to relative risks of the order of, say, 1.2 ± 1.5 which are very signi®cant, but eventually very hard to understand because they most probably re¯ect a relatively minor effect on the disease. I believe that, unless it is possible to sub-divide the population at risk by clear-cut clinical criteria, and through this identify a subset with a relative risk at least of the order of 2 ± 3, functional studies may not be worthwhile.
The intriguing difference in the incidence of prostate cancer between Africans and African-Americans as compared to white Europeans or Caucasoids was again raised by Judd Moul. 7 This population difference leads to a relative risk of 2 ± 3, which is quite striking. It raises the question as to what criteria might be used for screening African-American populations that are different from screening in the other population groups. A recent paper by Makridakis et al 8 found a 5-a-reductase missense variant that appeared to give a signi®cantly increased relative risk for prostate cancer, particularly in AfricanAmericans and Hispanics. Perhaps there is here an analogy with the genetic variations giving rise to haemaglobinopathies, in the sense that there may have been selection for any variants that increase testosterone levels in African populations. If so, there may then be a variety of different missense polymorphisms in some of the relevant genes, each of which can have a small effect on the testosterone level and so might have been selected for. Collectively, such variations might explain the difference in relative risk between African-American and other populations, which seems to be one case where a population difference most probably does have a genetic basis. If this were shown to be the case, then the appropriate genotypes for those missense variants associated with prostate cancer susceptibility could be used as a basis for screening. Those individuals who carry such variants should then be subject to a more systematic screening using PSA or other comparable assays. I do fervently hope that so-called`political correctness' will not get in the way of the research that will be needed to apply what I think could be enormously bene®cial genetic testing. A comparable example of a major ethnic difference is the relatively high frequency of certain BRCA1 and APC variants associated, respectively, with breast and colorectal cancer susceptibility in individuals of Ashkenazi Jewish descent. Certainly in the case of the APC variant, there is a strong argument for screening for the genetic variant and then following this with a colonoscopy to remove any adenomas and so greatly reduce the risk of colon carcinoma. It may well be necessary to educate both the populations involved and the clinicians, to accept the notion that there is bene®t to be gained from using appropriate information on ethnic differences to help deal with genetically based susceptibility.
In the absence of clear clues in prostate cancer to somatic mutations in tumour suppressor genes, candidates can be selected by analogy with what has been found in other tumour types. One possibility is that a gene such as APC, which is commonly mutated in colorectal tumours, may show epigenetic changes in other tumour types, speci®cally methylation in the promoter region. Thus, it may be that haplo-insuf®ciency, which would be the ®rst step in methylation-based suppression of expression of a gene, is not a suf®cient selective advantage in colorectal tissue but is, say, in the prostate. The intriguing studies done by Jack Schealkens on Ecadherin expression point in that direction and, indeed, methylation changes associated with reduced expression of E-cadherin have been described in colorectal cancers. 9 Other possible candidates are the transcription factors involved in the wnt pathway including the recently described snail factor. 10 Comparative genomic hybridization is another approach to looking for genetic changes. Tapio Visacorpi has described another clear example of gene ampli®ca-tion, using this approach, in p40, a component of the initiation of transcription factor, EIF3. Shiv Srivastava described an approach through identifying prostatespeci®c genes, including one that has no protein product. The question with this approach is whether prostatespeci®c genes are likely to be a source of good candidates for mutational analysis. The androgen pathway is certainly an example where prostate-speci®c genes are directly altered in prostate cancer. As already mentioned, chromosomal changes found by FISH-based karyotype analysis may also provide clues as to where to ®nd candidate genes, but the ensuing positional clonal may, even with considerable advances in genomic information, prove arduous. My strong preference lies in analysing intelligently chosen candidate genes, guided by thè cancer pathways' found in other cancers (see Table 1 ).
Cancer pathways
A possible categorization of key functional pathways, and genes associated with them is shown in Table 1 . First on the list for prostate cancer is the category of prostatespeci®c functions connected, in particular, with androgen production and regulation. Next, using especially the data that come from studying colorectal cancer, is the wnt pathway including genes such as APC, E-cadherin, b-catenin, axin, and related transcription factors such as snail. A third pathway involves the genes controlling the variety of steps leading to apoptosis. Given the importance of the balance between growth rate and apoptosis for the development of a cancer, there is an increasing number of examples of mutations in genes involved in the apoptotic pathway being selected for in cancers because they reduce the probability of apoptosis. This includes some of those genes which also increase mutation rates, such as p53 and the mismatch repair genes, particularly hMLH1 and hMSH2. 11 The cell cycle check point genes such as p15 and p16, may be included in this pathway. There is clear evidence that these genes may be altered in their expression by methylation rather than mutation in certain carcinomas, and this should be explored in prostate cancer. Also included as candidates must be the caspase proteolytic enzymes, the fas receptor and its ligand, and BCL2 and bax, all involved in the control of apoptosis, as discussed by Bill Watson. Next come the category of changes involving direct growth control, which includes a variety of growth factor receptors and their ligands as well as associated signalling molecules. It is striking that Water®eld's classic discovery, at the ICRF in 1984, of the relationship between a viral oncogene, erb-B and the epidermal growth factor receptor EGFR, which ®rst focused attention on the importance of growth factor receptor and growth factor changes, is only now being exploited at the clinical level 16 y later. Two examples are the production of drugs that interfere with the tyrosine kinase receptor activity of EGFR, as described by George Blackledge, 12 and the monoclonal antibody`Herceptin' marketed by Roche for breast cancer, directed against the receptor erb-B2, which is closely related in function to EGFR and ampli®ed in a subset of breast cancers.
Next on the list of pathways must come angiogenesis, as described so elegantly by Judah Folkman. However, I believe that selection for mutations enhancing tumour angiogenesis may be a relatively late step in the evolution of most carcinomas. Angiogenesis is probably relevant to tumour evolution at two levels. The ®rst is the normal angiogenic response to any form of wounding. Since early changes in epithelial architecture associated with tumorigenesis are closely analogous to wounding, this stage could elicit a normal angiogenic response which might be enough to satisfy the needs of early tumour development corresponding, say, to polyps or adenomas in the colon. The second stage may only arise much later, when a tumour has reached a suf®cient bulk that the normal angiogenic process is not suf®cient to satisfy its needs. This then will lead to an election for mutations that substantially increase angiogenesis in and around the tumour. It is clear from Judah Folkman's work that angiogenesis must be very tightly regulated, otherwise, for example, every time the skin was damaged by a cut there would be a risk of vascularization overtaking the wound healing process. There is perhaps an analogy here with the need for tight regulation of immune response to prevent the excesses that can be so damaging in leading to autoimmune disease.
Thus, a tumour's evolution has to work through that regime of tight regulation of angiogenesis, leading perhaps to stepwise selection of mutations appropriate to the need for different levels of angiogenesis as tumour evolution progresses. The long-term consequences of cyclic treatment with anti-angiogenic factors are unclear. There are bound to be escape mutations as in most other drug treatments. The obvious response to this is to use drugs in combination, as George Blackledge illustrated with his new drug against tyrosine kinase receptor activity working in combination with taxol. For example, in contrast to the common assumption that drugs may work best when they are killing dividing cells, since it is known that many current drugs and treatment effects mostly work through apoptosis, rather than direct cell killing, it may be easier to enhance speci®c killing by apoptosis when a tumour has been constrained by anti-angiogenic therapy to a static situation.
The last category of candidates are obviously those that are involved in selection against treatment. Here, Tapio Visacorpi's elegant analysis of the role of androgen treatment leading to selection for androgen receptor ampli®-cation variants is a classic example.
The Human Genome Project, when completed, will leave us with somewhere between 50 000 and 100 000 genes as the maximum number of potential candidates to screen for mutations in cancer. However, a combination of intelligent selection of candidate genes along the lines I have discussed above, together with information on localization and the applications of array technology for studying changes in gene expression, will surely all contribute to a narrowing down of the set of candidates. The ultimate goal is the complete de®nition of the set of genetic changes in any cancer and, in particular, those that are most often found in prostate cancer. Proteomic analysis of the expression of proteins, using two-dimensional gels, may also make an important contribution to screening for abnormalities in cancers. Overall, the key technology is high throughput and very ef®cient mutation detection.
Cancer prevention
Prevention is better than cure, but so far there are few, if any, clues to prevention of prostate cancer. Indeed, apart from smoking, the clues to cancer prevention in general are mostly poorly de®ned. It has always seemed to me to be fortunate that the general dietary advice for cancer prevention, namely to eat less fat and perhaps less in general, but to eat more fresh fruit and vegetables, happens to be good for the heart as well. There would indeed be a dilemma if one dietary regime was clearly good for the heart, while another complimentary approach was best for cancer. So, at best, one can suggest a`sensible' diet and clear-cut changes in incidence, like that in stomach cancer, may occur without it ever really being clear as to why. Dietary studies for cancer prevention are extremely dif®cult because it is likely to be the diet of 10, 15 or even 20 y ago that matters, and that can be very hard to establish. Even in cases where dietary effects are unequivocal, such as in breast and colon cancer, it is still unclear as to what in the diet is most relevant. Is it dietary fat, is it red meat, or is it an indirect effect of either of these on the bacterial¯ora in the gut?
There is a general tendency to assume that dietary and other environmental effects on cancer incidence are likely to be acting by causing mutations. However, the DNA sequence of mutations, for example, in APC and p53 in colon cancer as compared to mutations in p53 in lung cancer clearly suggest, as Curtis Harris and others have emphasized, that the environmental effects, at least on colon cancer, are very unlikely to be mutagenic. 13, 14 Thus, rather than looking for mutagenic effects of components of the diet it seems more likely that these, broadly speaking, have promotional effects, namely effects on the selective advantage of new mutations during cancer evolution and progression.
Prostate cancer screening PSA testing to monitor for prostate cancer recurrence is undoubtedly valuable, although even now the decision on how to treat may not be clear-cut. Improvement in the PSA screening technique, as described by Hans Lilja with his emphasis on free vs bound PSA and the use of its close relative HK2, clearly improve both speci®city and sensitivity. However, it still seems that more emphasis could be put, as I have mentioned in both the previous meetings, on approaches to isolating epithelial cells and measuring PSA or other products only in them, in order to get rid of background activity in other cells, however low, and thus further improve both sensitivity and speci®city.
However In any situation where a screening test gives a relatively high frequency of false positives, there is a need for a second level screen of those who test positive, which may be more invasive but must be much more cancerspeci®c. New developments in ultrasound imaging and the use of MRI, as described by Freddy Hamdy, 15 may help. I remain puzzled, however, why greater emphasis has not been put on improving immunoscintigraphy using good antibodies, for example, to the extracellular portion of PMSA. The use of antibodies to isolate epithelial cells from the blood was effectively described by Robert Vesella. Whether from the blood or the bone marrow, that should also be a powerful approach that needs further investigation.
Treatment and prognosis
I ®nd it hard to accept any argument for ever delaying androgen-based or hormone-based treatments once it is clear that some treatment is needed. Biologically it seems to make no sense whatever to delay. The question raised by Fritz Schroeder as to the problem of continuous treatment for as long as 17 or 18 y may be answered by Anthony D'Amico's investigations, 16 which suggest that there may be no advantage to be gained from a hormonebased treatment beyond 2 y. Even with tamoxifen adjuvant treatment for breast cancer, it is not clear how long to continue. The argument in that case may be that, once the major bene®t of hormone treatment of the cancer has been achieved after perhaps a relatively short period of time, there may still be bene®t through prevention of a second primary breast cancer. The same could perhaps be true for the prostate, although it is much less likely to be relevant given the generally late age of onset of prostate cancer.
An important point was made by Jan Adolfsson in distinguishing between prognosis and treatment prediction. I have long argued with my colleagues, pathologists and clinicians, that prognostic factors are of little value unless they really do contribute to treatment decisions. Prognosis often is little more than a measure of age, and can be similar for cancers with very different underling evolutionary histories. However, for example, a p53 mutation or an ampli®ed erb-B2, may provide the basis of immunotherapy which determines the outcome, while having no, or even contrary, prognostic value in the absence of targeted treatment. The case of the erb-B2 positive subset of breast cancers is particularly instructive, since in that case it is known that in the absence of distinguishing treatment the prognosis is worse, and yet with the newly available treatment with a monoclonal antibody combined with taxol the result may be exactly the opposite. Thus, especially in the future as more treatments are tailored to the biology of cancer, it may be this biology that determines the outcome through the appropriate treatment, even if the a priori prognosis is worse.
The description of the bone morphogenetic protein, BMP6 ( a member of the TGFb family) and its strong correlation with prognosis by Hamdy 15 was very interesting. These data indicate that when BMP6 is expressed, survival is much worse. In this case, BMP6 might well prove an effective therapeutic target for those poor prognosis prostate cancers in which it is expressed.
There is still clearly a need for new effective therapies. John Trachtenberg described an intriguing high technology transperineal thermal treatment and, as in previous meetings, there were a variety of suggestions for immunotherapies. This, I still believe, is one of the most promising general avenues to pursue for cancer treatment. There was no new discussion of monoclonal antibody-based therapy, although this is the one area of immunotherapy that has so far clearly entered clinical practice. Approaches to T-cell immunotherapy, as described by Dalgleish 17 and other strategies such as Srivastava's use of heatshock proteins as carriers of immunogenic peptides or Thierry Boon's more targeted approach based on his elegant identi®cation of tumour-speci®c or associated antigens, will undoubtedly be part of the oncologist's treatment armoury in the future. Beyond that, the drugs of the future will come mostly from the discovery of genes and pathways in cancer evolution identifying targets for small molecular weight compound inhibitors or agonists. A supreme example of this is George Blackledge's description of the tyrosine kinase receptor blocking drug. This also shows how long the interval between an initial basic discovery, in this case, of the relationship between the erb-B oncogene and the epidermal growth factor receptor, and the subsequent development of a clinically effective drug can be Ð no less than 16 y in this case. Undoubtedly further examples will be found of drugs which block tyrosine kinase receptor activities associated with other growth factor receptors.
Conclusion
At this meeting there was little discussion of the social and psychological impacts of prostate cancer and its treatment. There is clearly a problem in dealing with the anxiety that comes from PSA screening and the decisions which have to be made by the individual found to be positive. There are intriguing differences between men and women in their attitude to treatment choices. Senator Dole, in his address to the meeting, emphasized the need for an informed public to accept new approaches to screening and therapy. There is, furthermore, a clear need for further studies on the behavioural effects of treatments and their side effects. Perhaps these behavioural issues can be a topic to focus on in a future meeting.
A unique feature of the prostate cancer forums is the way in which they bring together such a wide range of people, including clinicians from many disciplines, laboratory scientists, social scientists, and patients and supporters of the Prostate Cancer Trust. It is a remarkable forum for bringing people together and one which continues to generate new collaborations and stimulate sharing of research materials. We owe an enormous debt to Clive Bourne for his initiation of the Trust and his continued support, and to all those involved in the scienti®c and other aspects of the organization of a most stimulating and constructive meeting.
